Fierce Biotech August 28, 2024
Flagship Pioneering and Pfizer have added Quotient into their 10-program partnership, inking a deal to discover new targets for two programs in cardiovascular and renal diseases.
The deal fits into a larger equation: Back in July 2023, Pfizer and Flagship Pioneering each put down $50 million to build a 10-program pipeline. The Big Pharma said the VC firm and its bioplatform companies could make up to $700 million in biobucks for each successful drug that emerges from the pact.
Now, Flagship-founded Quotient will work with Flagship’s drug development arm—dubbed Pioneering Medicines—to spot somatic mutations in genes that change the progression of heart and kidney diseases, according to an Aug. 28 release.
“Quotient’s somatic genomics platform explores the extensive genetic...
Today's Sponsors
Today's Sponsor